Loading...
Loading...
In a report published Tuesday, Bank of America analyst Bob Hopkins moved the rating on
CareFusion CorporationCFN from Buy to No Rating, and removed the $50.00 price target.
In the report, Bank of America noted, “On Sunday night, BDX announced it had entered into a definitive agreement to acquire CFN for $12.2bn, or $58 per share, a 26% premium to Friday's close. This equates to 21.6x consensus 2015E cash EPS and 12x consensus 2015E EBITDA. CFN shareholders are being offered $49 cash & 0.0777 shares of BDX for each share of CFN owned. We are moving our rating on CFN shares to No Rating due to the acquisition agreement and given that the shares are no longer trading on fundamentals. Investors should not rely on our previous ratings or price objectives.”
CareFusion Corporation closed on Monday at $56.75.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in